Corsera Health announced it raised an oversubscribed $80 million Series A to advance its cardiovascular disease prediction-and-prevention strategy and to fund development of once-annual preventive RNAi medicines targeting the two primary drivers of atherosclerotic cardiovascular disease (ASCVD): elevated LDL cholesterol and high blood pressure. The round was co-led by Forbion and Population Health Partners, with participation from additional investors including Corsera co-founder and co-CEO John Maraganore, Ph.D. As part of the financing, Forbion general partner Marco Boorsma, Ph.D., will join Corsera’s board.
Alongside the financing, Corsera reported a key clinical milestone: the company has initiated dosing in a Phase 1 trial of COR-1004, a subcutaneously administered siRNA targeting PCSK9. The study’s primary endpoint is safety and tolerability, with secondary measures including PCSK9 knockdown, LDL-C lowering, and pharmacokinetics. Corsera expects initial proof-of-concept data in 2026.
Corsera said the Series A will also support development of COR-2003, an siRNA targeting angiotensinogen (AGT) to reduce blood pressure, with a Phase 1 trial anticipated to begin in mid-2026. In parallel, the company plans continued work on Klotho, its proprietary AI-enabled platform designed to predict lifetime cardiovascular disease risk and quantify the potential benefit of lowering LDL-C and blood pressure to extend cardiovascular healthspan.
KEY QUOTES:
“At Corsera, we are motivated by a bold vision: a world without cardiovascular disease. We are making strong progress toward a future in which preventive care enables people to live longer, healthier lives, and the initiation of our first clinical trial marks an important milestone on that journey.”
Clive Meanwell, M.D., Co-Founder and Co-CEO, Corsera Health; Managing Partner, Population Health Partners
“With this financing and the start of our first clinical trial, we are entering a pivotal next phase for the company. By combining AI-enabled prediction of lifetime ASCVD risk with preventive RNAi medicines, Corsera has the potential to change the trajectory of cardiovascular disease, enabling earlier intervention and broad access to prevention at a population scale.”
John Maraganore, Ph.D., Co-Founder and Co-CEO, Corsera Health
“Corsera Health exemplifies the kind of bold, science-driven innovation that Forbion aims to support and scale. The company’s integrated approach, combining durable RNAi therapeutics with advanced predictive technology, has the potential to fundamentally shift cardiovascular care from late intervention to true prevention. The Corsera team brings exceptional scientific depth, drug development expertise, and a clear vision for global impact. We are excited to partner closely with the company as it advances toward clinical validation and builds a category-defining cardiovascular prevention platform.”
Marco Boorsma, Ph.D., General Partner, Forbion
